Enzyme Replacement Therapy Market Share & Statistics, 2032

Enzyme Replacement Therapy Market Size - By Enzyme (Alglucosidase alfa, Agalsidase beta, Imiglucerase), Indication (Gaucher, MPS, Pompe, SCID, Fabry), Route of Administration, End-user, Global Forecast 2024-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculation

1.4&nbsp;&nbsp;&nbsp; Covid-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Enzyme replacement therapy 3600&nbsp;synopsis, 2018 &ndash; 2032 (USD Million)

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Region trends

2.1.3&nbsp;&nbsp;&nbsp; Enzyme type trends

2.1.4&nbsp;&nbsp;&nbsp; Indication trends

2.1.5&nbsp;&nbsp;&nbsp; Route of Administration trends

2.1.6&nbsp;&nbsp;&nbsp; End-user trends

Chapter 3&nbsp;&nbsp;&nbsp;Enzyme Replacement Therapy Market Insights

3.1&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032 (USD Million)

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing incidence of rare genetic disorders

3.2.1.2&nbsp;&nbsp;&nbsp;Rising demand for effective treatment options

3.2.1.3&nbsp;&nbsp;&nbsp;Growing awareness of rare genetic diseases

3.2.1.4&nbsp;&nbsp;&nbsp;Advancements in biotechnology and genetic engineering

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost of therapy

3.2.2.2&nbsp;&nbsp;&nbsp;Limited availability of ERT products

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By enzyme type

3.3.2&nbsp;&nbsp;&nbsp; By indication

3.3.3&nbsp;&nbsp;&nbsp; By route of administration

3.3.4&nbsp;&nbsp;&nbsp; By end-user

3.3.5&nbsp;&nbsp;&nbsp; By region

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Technology landscape

3.7&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.4&nbsp;&nbsp;&nbsp; Strategic dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Enzyme Replacement Therapy Market Estimates and Forecast, By Enzyme Type, 2018-2032 (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by enzyme type

5.2&nbsp;&nbsp;&nbsp; Imiglucerase

5.3&nbsp;&nbsp;&nbsp; Agalsidase beta

5.4&nbsp;&nbsp;&nbsp; Taliglucerase

5.5&nbsp;&nbsp;&nbsp; Velaglucerase alfa

5.6&nbsp;&nbsp;&nbsp; Laronidase

5.7&nbsp;&nbsp;&nbsp; Alglucosidase alfa

5.8&nbsp;&nbsp;&nbsp; Galsulfase

5.9&nbsp;&nbsp;&nbsp; Idursulfase

5.10&nbsp;&nbsp;&nbsp; Pancreatic enzymes

5.11&nbsp;&nbsp;&nbsp; Pegademase

5.12&nbsp;&nbsp;&nbsp; Other enzyme types

Chapter 6&nbsp;&nbsp;&nbsp;Enzyme Replacement Therapy Market Estimates and Forecast, By Indication, 2018-2032 (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by indication

6.2&nbsp;&nbsp;&nbsp; Gaucher disease

6.3&nbsp;&nbsp;&nbsp; Fabry disease

6.4&nbsp;&nbsp;&nbsp; Pompe disease

6.5&nbsp;&nbsp;&nbsp; Plasma cell disorders

6.6&nbsp;&nbsp;&nbsp; SCID

6.7&nbsp;&nbsp;&nbsp; Mucopolysaccharidosis (MPS)

6.7.1&nbsp;&nbsp;&nbsp; MPS I - Hurler, Hurler Scheie and Scheie

6.7.2&nbsp;&nbsp;&nbsp; MPS II - Hunter

6.7.3&nbsp;&nbsp;&nbsp; MPS III - Sanfilippo

6.7.4&nbsp;&nbsp;&nbsp; Other mucopolysaccharidosis

6.8&nbsp;&nbsp;&nbsp; Other indications

Chapter 7&nbsp;&nbsp;&nbsp;Enzyme Replacement Therapy Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by route of administration

7.2&nbsp;&nbsp;&nbsp; Parenteral

7.3&nbsp;&nbsp;&nbsp; Oral

Chapter 8&nbsp;&nbsp;&nbsp;Enzyme Replacement Therapy Market Estimates and Forecast, By End-user, 2018-2032 (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by end-user

8.2&nbsp;&nbsp;&nbsp; Hospitals

8.3&nbsp;&nbsp;&nbsp; Infusion centers

8.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 9&nbsp;&nbsp;&nbsp;Enzyme Replacement Therapy Market Estimates and Forecast, By Region, 2018-2032 (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Sanofi

10.2&nbsp;&nbsp;&nbsp; Biomarin Pharmaceutical Inc.

10.3&nbsp;&nbsp;&nbsp; AbbVie Inc.

10.4&nbsp;&nbsp;&nbsp; Pfizer, Inc.

10.5&nbsp;&nbsp;&nbsp; Alexion Pharmaceuticals Inc.

10.6&nbsp;&nbsp;&nbsp; Allergan plc

10.7&nbsp;&nbsp;&nbsp; Horizon Pharma Public Limited Company

10.8&nbsp;&nbsp;&nbsp; Recordati Rare Diseases

10.9&nbsp;&nbsp;&nbsp; Protalix Biotherapeutics

10.10&nbsp;&nbsp;&nbsp; Amicus Therapeutics, Inc. 
&nbsp;

Enzyme Replacement Therapy Market

Customize This Report